Erasca is a cash-burning early-stage biotechnology company with all value concentrated in two Phase 1 clinical programs and a quality profile well below the minimum acceptable floor; the stock has broken out technically — above all key moving averages with a golden cross, RSI at 70, and rising institutional interest — and offers 26.6% headroom to the analyst target at a roughly 3.8-to-1 favorable risk/reward, but the absence of commercial operations, negative free cash flow, and a large recent earnings miss mean quality risk dominates the setup.
Thesis pillars
- Favorable Upside Asymmetry→Stable
- Quality Below Minimum Floor→Stable
- Clinical Pipeline Concentration→Stable
- +1 more pillar — see the Why tab for full reasoning
Erasca, Inc. (ERAS) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $19.67: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum.
Erasca is a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, with two Phase 1 clinical programs — ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) — and no approved products or revenue. The company reported a net loss of... Read more
Sell if holding. Engine safety override at $19.67: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.4/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 16d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-27Recent Developments — Erasca, Inc.
Latest news
- NEWS Morgan Stanley Maintains Equal-Weight on Erasca, Raises Price Target to $21 — benzinga Jul 20, 2026 neutral
- NEWS Erasca Unveils Updated Cancer Candidate Progress, Maps Path Toward Pivotal Cancer Trials — benzinga Jul 14, 2026 positive
- NEWS B of A Securities Maintains Neutral on Erasca, Raises Price Target to $18 — benzinga Jul 14, 2026 positive
- NEWS Reported Earlier, Erasca Announces Pricing Of Upsized Public Offering Of 31,428,572 Common Shares At $17.50 Per Share — benzinga Jul 14, 2026 positive
- NEWS Erasca Plans To Commence $500M Common Stock Offering — benzinga Jul 13, 2026 negative
Generated 2026-07-27T14:48:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineERAS-0015 and ERAS-4001 Phase 1 programs10-K Item 1A: 'AURORAS-1 and BOREALIS-1 Phase 1 trials for ERAS-0015 and ERAS-4001 ... all of our other programs are still in the preclinical or discovery stage'
- MEDIUMSupplierJoyo10-K Item 1: 'ERAS-0015, which we license from Guangzhou Joyo Pharmatech Co., Ltd. (Joyo)'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.67: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $18.22. Score 4.4/10, moderate confidence.
Take-profit target: $19.84 (+1.2% upside). Prior stop was $18.22. Stop-loss: $18.22.
Concentration risk — Pipeline: ERAS-0015 and ERAS-4001 Phase 1 programs; Target reached (1.2% upside); Quality below floor (1.6 < 4.0).
Erasca, Inc. trades at a P/E of N/A (forward -34.6). TrendMatrix value score: 5.0/10. Verdict: Sell.
17 analysts cover ERAS with a consensus score of 4.1/5. Average price target: $23.
What does Erasca, Inc. do?Erasca is a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, with two Phase 1...
Erasca is a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, with two Phase 1 clinical programs — ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) — and no approved products or revenue. The company reported a net loss of $124.5 million for 2025 and an accumulated deficit of $892.2 million as of December 31, 2025.